Abstract
Didemnin B, a dipsipeptide isolated from the Caribbean tunicate Trididemnum with antitumor and antiviral activity was evaluated in a phase II trial in the treatment of metastatic, hormonally refractory adenocarcinoma of the prostate. Thirteen patients were treated with didemnin B at 3.5 mg/m2 and 20 patients were treated at 6.3 mg/m2 intravenously every 28 days. Response was assessed every 8 weeks. Of 32 evaluable patients there was one partial response for an overall response rate of 3% (95% confidence interval of 0.1-16%). The most common toxicities were nausea, vomiting, and diarrhea. Serious cardiac and pulmonary toxicities were also noted. This drug does not appear to warrant further evaluation in this disease as a single agent.
Original language | English (US) |
---|---|
Pages (from-to) | 167-170 |
Number of pages | 4 |
Journal | Investigational New Drugs |
Volume | 13 |
Issue number | 2 |
DOIs | |
State | Published - Jun 1995 |
Externally published | Yes |
Keywords
- didemnin B
- phase II
- prostate cancer
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Pharmacology (medical)